Comerica Bank
RCKT icon

Comerica Bank’s Rocket Pharmaceuticals RCKT Stock Holding History

Comerica Bank’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$477 Sell
136
-1,222
-90% -$4.18K ﹤0.01% 3639
2025
Q3 		$4.43K Buy
1,358
+1,070
+372% +$3.37K ﹤0.01% 3416
2025
Q2 		$706 Sell
288
-815,701
-100% -$4.13M ﹤0.01% 3599
2025
Q1 		$5.44M Buy
815,989
+35,609
+5% +$352K 0.02% 622
2024
Q4 		$9.81M Sell
780,380
-5,146
-0.7% -$77.5K 0.04% 418
2024
Q3 		$14.5M Buy
785,526
+98,872
+14% +$2.03M 0.06% 326
2024
Q2 		$14.8M Buy
686,654
+152,129
+28% +$3.49M 0.06% 299
2024
Q1 		$14.4M Sell
534,525
-23,500
-4% -$668K 0.06% 313
2023
Q4 		$16.7M Buy
558,025
+117,949
+27% +$2.6M 0.08% 248
2023
Q3 		$9.02M Buy
+440,076
New +$8M 0.05% 393
2022
Q4 		$6.36M Buy
288,316
+39,806
+16% +$733K 0.05% 455
2022
Q3 		$4.07M Buy
248,510
+50
+0% +$780 0.03% 629
2022
Q2 		$4.15M Buy
248,460
+116,503
+88% +$1.39M 0.03% 628
2022
Q1 		$1.8M Buy
131,957
+2,940
+2% +$50.8K 0.01% 1218
2021
Q4 		$2.12M Buy
129,017
+12,787
+11% +$349K 0.02% 1125
2021
Q3 		$3.42M Sell
116,230
-3,962
-3% -$144K 0.02% 926
2021
Q2 		$3.3M Buy
120,192
+39,487
+49% +$1.71M 0.02% 984
2021
Q1 		$3.62M Buy
80,705
+24,894
+45% +$1.37M 0.02% 950
2020
Q4 		$3.07M Buy
55,811
+26,665
+91% +$972K 0.02% 1026
2020
Q3 		$819K Buy
29,146
+3,280
+13% +$80.8K 0.01% 1677
2020
Q2 		$655K Sell
25,866
-5,285
-17% -$95.3K 0.01% 1745
2020
Q1 		$541K Buy
31,151
+4,086
+15% +$80.9K 0.01% 1695
2019
Q4 		$596K Sell
27,065
-1,090
-4% -$18.2K ﹤0.01% 1821
2019
Q3 		$363K Buy
28,155
+7,329
+35% +$91K ﹤0.01% 1997
2019
Q2 		$263K Buy
+20,826
New +$363K ﹤0.01% 2118

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Comerica Bank's RCKT Position: Q4 2025 in Review

Comerica Bank reduced its Rocket Pharmaceuticals (RCKT) stake by 90% in Q4 2025, selling an estimated $4.18K and leaving 136 shares worth $477. The position accounts for ﹤0.01% of the portfolio, ranked #3639.

Comerica Bank first reported a position in RCKT in Q2 2019 and has held it in 25 quarters since. The position peaked at $16.7M in Q4 2023. 186 funds tracked by Wall St. Rank hold RCKT as of Q4 2025.

  • Comerica Bank held 136 shares of Rocket Pharmaceuticals worth $477 as of Q4 2025.
  • Comerica Bank sold 1,222 Rocket Pharmaceuticals shares in Q4 2025, an estimated $4.18K.
  • Rocket Pharmaceuticals made up ﹤0.01% of Comerica Bank's portfolio in Q4 2025, its #3639 holding.
  • Comerica Bank first reported a position in Rocket Pharmaceuticals in Q2 2019 and has held it in 25 quarters since.
  • Comerica Bank's Rocket Pharmaceuticals position peaked at $16.7M in Q4 2023.
  • 186 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q4 2025.

Based on Comerica Bank's 13F filing for Q4 2025, filed 29 Jan 2026.